Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results
Financial Performance Overview: Ridgetech, Inc. reported stable revenue of approximately $120 million for the fiscal year ending March 31, 2025, despite a 3.2% decrease from the previous year. The company achieved a net income of $10.20 million, a significant turnaround from a net loss of $4.23 million in the prior year.
Strategic Business Transformation: The company underwent significant changes, including divesting its retail pharmacy business and acquiring Ridgeline and Allright to enhance its wholesale distribution capabilities in both online and offline markets, reflecting a strategic shift towards the wholesale pharmaceutical sector amidst increasing competition in China's healthcare industry.
Trade with 70% Backtested Accuracy
Analyst Views on RDGT
About RDGT
About the author
Ridgetech Unveils Dual-Engine Growth Strategy for 2026
- Supply Chain Integration Strategy: Ridgetech plans to enhance its competitiveness in China's pharmaceutical and healthcare market by integrating its wholesale distribution network and B2B platform, which is expected to accelerate the transition from a traffic-driven to a value-driven business model.
- Digital Innovation Driving Growth: Subsidiary Allright will serve as the core digital engine, aiming to expand its customer base to 300,000 in 2026, achieve a 30% year-on-year increase in new B2B customers, and exceed a 30% online business penetration rate, further enhancing market influence.
- Synergistic Dual-Engine Effects: Ridgetech will integrate its offline wholesale platform Jiuxin Medicine with Allright to optimize procurement and sales processes, improving response speed and operational agility, thereby achieving higher turnover efficiency.
- Management Strategic Outlook: CEO Frank Zhao stated that the company is committed to achieving its 2026 and medium- to long-term strategic objectives through a clear strategic roadmap and an open collaborative framework, driving high-quality development and enhancing market position.
Ridgetech Unveils Dual-Engine Growth Strategy for 2026
- Supply Chain Integration Strategy: Ridgetech plans to achieve dual breakthroughs in business model innovation and value creation in 2026 by integrating its wholesale distribution network and B2B platform, thereby strengthening its long-term growth foundation in China's pharmaceutical and healthcare supply chain.
- Core Business Enhancement: The company aims to further enhance the competitiveness of its wholesale business by deepening strategic cooperation with core suppliers and expanding distribution coverage of high-margin brands, which is expected to accelerate its transformation from a traffic-driven to a value-driven business model.
- Digital Innovation Driving Growth: Ridgetech's wholly-owned subsidiary Allright will serve as the core digital engine, targeting to expand its customer base to 300,000, achieve a 30% year-on-year increase in new B2B customers, and exceed a 30% online business penetration rate in 2026.
- Synergistic Dual-Engine Effects: Ridgetech plans to systematically introduce Jiuxin Medicine's supply chain products onto the Allright platform, optimizing procurement and sales processes to enhance operational agility, thereby establishing a virtuous cycle where
Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results
Financial Performance Overview: Ridgetech, Inc. reported stable revenue of approximately $120 million for the fiscal year ending March 31, 2025, despite a 3.2% decrease from the previous year. The company achieved a net income of $10.20 million, a significant turnaround from a net loss of $4.23 million in the prior year.
Strategic Business Transformation: The company underwent significant changes, including divesting its retail pharmacy business and acquiring Ridgeline and Allright to enhance its wholesale distribution capabilities in both online and offline markets, reflecting a strategic shift towards the wholesale pharmaceutical sector amidst increasing competition in China's healthcare industry.
Ridgetech Unveils Dual-Engine Growth Strategy for 2026
- Supply Chain Integration Strategy: Ridgetech plans to enhance its competitiveness in China's pharmaceutical and healthcare market by integrating its wholesale distribution network and B2B platform, which is expected to accelerate the transition from a traffic-driven to a value-driven business model.
- Digital Innovation Driving Growth: Subsidiary Allright will serve as the core digital engine, aiming to expand its customer base to 300,000 in 2026, achieve a 30% year-on-year increase in new B2B customers, and exceed a 30% online business penetration rate, further enhancing market influence.
- Synergistic Dual-Engine Effects: Ridgetech will integrate its offline wholesale platform Jiuxin Medicine with Allright to optimize procurement and sales processes, improving response speed and operational agility, thereby achieving higher turnover efficiency.
- Management Strategic Outlook: CEO Frank Zhao stated that the company is committed to achieving its 2026 and medium- to long-term strategic objectives through a clear strategic roadmap and an open collaborative framework, driving high-quality development and enhancing market position.
Ridgetech Unveils Dual-Engine Growth Strategy for 2026
- Supply Chain Integration Strategy: Ridgetech plans to achieve dual breakthroughs in business model innovation and value creation in 2026 by integrating its wholesale distribution network and B2B platform, thereby strengthening its long-term growth foundation in China's pharmaceutical and healthcare supply chain.
- Core Business Enhancement: The company aims to further enhance the competitiveness of its wholesale business by deepening strategic cooperation with core suppliers and expanding distribution coverage of high-margin brands, which is expected to accelerate its transformation from a traffic-driven to a value-driven business model.
- Digital Innovation Driving Growth: Ridgetech's wholly-owned subsidiary Allright will serve as the core digital engine, targeting to expand its customer base to 300,000, achieve a 30% year-on-year increase in new B2B customers, and exceed a 30% online business penetration rate in 2026.
- Synergistic Dual-Engine Effects: Ridgetech plans to systematically introduce Jiuxin Medicine's supply chain products onto the Allright platform, optimizing procurement and sales processes to enhance operational agility, thereby establishing a virtuous cycle where
Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results
Financial Performance Overview: Ridgetech, Inc. reported stable revenue of approximately $120 million for the fiscal year ending March 31, 2025, despite a 3.2% decrease from the previous year. The company achieved a net income of $10.20 million, a significant turnaround from a net loss of $4.23 million in the prior year.
Strategic Business Transformation: The company underwent significant changes, including divesting its retail pharmacy business and acquiring Ridgeline and Allright to enhance its wholesale distribution capabilities in both online and offline markets, reflecting a strategic shift towards the wholesale pharmaceutical sector amidst increasing competition in China's healthcare industry.
